The time has come to make cervical cancer prevention an essential part of comprehensive sexual and reproductive health services for HIV-positive women in low-income countries

Journal of the International AIDS Society

Volumn 18, Issue , 2015, Pages

  Huchko, Megan J ^a   Maloba, May ^b   Nakalembe, Miriam ^c   Cohen, Craig R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^c MAKERERE UNIVERSITY   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PREVENTION; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; EPIDEMIC; HEALTH CARE DISPARITY; HEALTH CARE NEED; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LOWEST INCOME GROUP; NOTE; PRIORITY JOURNAL; PUBLIC HEALTH; REPRODUCTIVE HEALTH; SECONDARY PREVENTION; SEXUAL HEALTH; UTERINE CERVIX CANCER; WART VIRUS; ADULT; COMPLICATION; DEVELOPING COUNTRY; EARLY CANCER DIAGNOSIS; FEMALE; HEALTH SERVICE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; POVERTY; UTERINE CERVICAL NEOPLASMS;

ADULT; DEVELOPING COUNTRIES; EARLY DETECTION OF CANCER; FEMALE; HIV INFECTIONS; HUMANS; POVERTY; REPRODUCTIVE HEALTH SERVICES; UTERINE CERVICAL NEOPLASMS;

EID: 84960158350     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.18.6.20282     Document Type: Note

References (49)

1. Farmer P, Frenk J, Knaul FM, Shulman LN, Alleyne G, Armstrong L, et al. Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet. 2010;376:1186-93.
2. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer; 2010.
3. Adefuye PO, Broutet NJ, de Sanjose S, Denny LA. Trials and projects on cervical cancer and human papillomavirus prevention in sub-Saharan Africa. Vaccine. 2013;31(Suppl 5):F53-9.
4. Gustafsson L, Ponten J, Bergstrom R, Adami HO. International incidence rates of invasive cervical cancer before cytological screening. Int J Cancer. 1997;71:159-65.
5. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-86.
6. Ezechi OC, Ostergren PO, Nwaokorie FO, Ujah IA, Odberg Pettersson K. The burden, distribution and risk factors for cervical oncogenic human papilloma virus infection in HIV positive Nigerian women. Virol J. 2014;11:5.
7. Palefsky J. Biology of HPV in HIV infection. Adv Dent Res. 2006;19:99-105.
8. Blitz S, Baxter J, Raboud J, Walmsley S, Rachlis A, Smaill F, et al. Evaluation of HIV and highly active antiretroviral therapy on the natural history of human papillomavirus infection and cervical cytopathologic findings in HIV-positive and high-risk HIV-negative women. J Infect Dis. 2013;208:454-62.
9. Bratcher LF, Sahasrabuddhe VV. The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: current evidence and directions for future research. Infect Agents Cancer. 2010;5:8.
10. Patrelli TS, Gizzo S, Peri F, Franchi L, Volpi L, Esposito F, et al. Impact of highly active antiretroviral therapy on the natural history of cervical precancerous lesions: a 17-year institutional longitudinal cohort study. Reprod Sci. 2013;21:837-45.
11. Dryden-Peterson S, Medhin H, Kebabonye-Pusoentsi M, Seage GR 3rd, Suneja G, Kayembe MK, et al. Cancer incidence following expansion of HIV treatment in Botswana. PLoS One. 2015;10:e0135602.
12. Piketty C, Selinger-Leneman H, Grabar S, Duvivier C, Bonmarchand M, Abramowitz L, et al. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS. 2008;22:1203-11.
13. Franceschi S, Jaffe H. Cervical cancer screening of women living with HIV infection: a must in the era of antiretroviral therapy. Clin Infect Dis. 2007;45:510-3.
14. FHI360. In: integration of HIV and noncommunicable disease care. [cited 2015 May 1]. Accessed http://www.fhi360.org/sites/default/files/media/documents/NCD-Factsheet-v3-WEB.pdf
15. Haraka F, Glass TR, Sikalengo G, Gamell A, Ntamatungiro A, Hatz C, et al. A bundle of services increased ascertainment of tuberculosis among HIV-infected individuals enrolled in a HIV cohort in rural sub-Saharan Africa. PLoS One. 2015;10:e0123275.
16. Suthar AB, Rutherford GW, Horvath T, Doherty MC, Negussie EK. Improving antiretroviral therapy scale-up and effectiveness through service integration and decentralization. AIDS. 2014;28(Suppl 2):S175-85.
17. Dickinson C, Attawell K, Druce N. Progress on scaling up integrated services for sexual and reproductive health and HIV. Bull World Health Organ. 2009;87:846-51.
18. Dhana A, Luchters S, Moore L, Lafort Y, Roy A, Scorgie F, et al. Systematic review of facility-based sexual and reproductive health services for female sex workers in Africa. Global Health. 2014;10:46.
19. Hope R, Kendall T, Langer A, Barnighausen T. Health systems integration of sexual and reproductive health and HIV services in sub-Saharan Africa: a scoping study. J Acquir Immune Defic Syndr. 2014;67(Suppl 4):S259-70.
20. IPPF, UNFPA, WHO, UNAIDS, GNP+, ICW, et al. Rapid assessment tool for sexual and reproductive health and HIV linkages [Internet]. 2009 [cited 2015 May 6]. Available from: http://data.unaids.org/pub/Manual/2009/2009-rapid-assesment-brochure-en.pdf
21. World Health Organization. Sexual and reproductive health of women living with HIV/AIDS: guidelines on care, treatment and support for women living with HIV/AIDS and their children in resource-constrained settings. Geneva, Switzerland: World Health Organization; 2006.
22. World Health Organization. Operations manual for delivery of HIV prevention, care and treatment at primary health centers in high-prevalence, resource-constrained settings. Geneva, Switzerland: World Health Organization; 2008.
23. World Health Organization. Priority interventions + HIV/AIDS prevention, treatment and care in the health sector. Geneva, Switzerland: World Health Organization; 2010.
24. Rosser JI, Hamisi S, Njoroge B, Huchko MJ. Barriers to cervical cancer screening in rural Kenya: perspectives from a provider survey. J Community Health. 2015;40(4):756-61.
25. Seto K, Marra F, Raymakers A, Marra CA. The cost effectiveness of human papillomavirus vaccines: a systematic review. Drugs. 2012;72:715-43.
26. Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine. 2008;26:4080-93.
27. Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ. 2012;344:e1401.
28. Parry J. Vaccinating against cervical cancer. Bull World Health Organ. 2007;85:89-90.
29. GAVI Alliance. Human papillomavirus vaccine support [Internet]. 2013 [cited 2015 May 5]. Available from: http://www.gavialliance.org/support/nvs/human-papillomavirus-vaccine-support/
30. Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R, Swaminathan R, Shanthakumari S, et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet. 2007;370:398-406.
31. Sankaranarayanan R, Nene BM, Dinshaw K, Rajkumar R, Shastri S, Wesley R, et al. Early detection of cervical cancer with visual inspection methods: a summary of completed and on-going studies in India. Salud Publica Mex. 2003;45(Suppl 3):S399-407.
32. World Health Organization. Choosing interventions that are cost effective: cost-effectiveness thresholds [Internet]. 2005 [cited 2011 Sep 28]. Available from: http://www.who.int/choice/costs/CER-thresholds/en/index.html
33. Sankaranarayanan R, Nene BM, Dinshaw KA, Mahe C, Jayant K, Shastri SS, et al. A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India. Int J Cancer. 2005;116:617-23.
34. Huchko MJ, Sneden J, Zakaras JM, Smith-McCune K, Sawaya G, Maloba M, et al. A randomized trial comparing the diagnostic accuracy of visual inspection with acetic acid to visual inspection with Lugol's iodine for cervical cancer screening in HIV-infected women. PLoS One. 2015;10:e0118568.
35. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahe C, et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Eng J Med. 2005;353:2158-68.
36. Goldie SJ, Freedberg KA, Weinstein MC, Wright TC, Kuntz KM. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus. Am J Med. 2001;111:140-9.
37. Moses E, Pedersen HN, Mitchell SM, Sekikubo M, Mwesigwa D, Singer J, et al. Uptake of community-based, self-collected HPV testing vs. visual inspection with acetic acid for cervical cancer screening in Kampala, Uganda: preliminary results of a randomised controlled trial. Trop Med Int Health. 2015;20(10):1355-67.
38. Evaluating a Community-Driven Cervical Cancer Prevention Strategy in Western Kenya. [cited 2015 May 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02124252
39. WHO. Comprehensive cervical cancer prevention and control: a healthier future for girls and women. WHO Guidance Note. Geneva, Switzerland: WHO; 2013.
40. Church K, Wringe A, Fakudze P, Kikuvi J, Simelane D, Mayhew SH, et al. Are integrated HIV services less stigmatizing than stand-alone models of care? A comparative case study from Swaziland. J Int AIDS Soc. 2013;16:17981, doi: http://dx.doi.org/10.7448/IAS.16.1.17981
41. Mak J, Birdthistle I, Church K, Friend-Du Preez N, Kivunaga J, Kikuvi J, et al. Need, demand and missed opportunities for integrated reproductive health-HIV care in Kenya and Swaziland: evidence from household surveys. AIDS. 2013;27(Suppl 1):S55-63.
42. Ekong J, Kakande C, Mutabazi M, Kakande H, Castano F, Uhuru K, et al. Integration of cervical cancer screening using visual inspection with acetic acid and cryotherapy treatment into HIV/AIDS services in rural districts of Western Uganda. In: Oral Abstract: International AIDS Society. Kuala Lumpur; 2013.
43. Mutyaba T, Mirembe F, Sandin S, Weiderpass E. Evaluation of 'see-see and treat' strategy and role of HIV on cervical cancer prevention in Uganda. Reprod Health. 2010;7:4.
44. Denny LA, Sankaranarayanan R, De Vuyst H, Kim JJ, Adefuye PO, Alemany L, et al. Recommendations for cervical cancer prevention in sub-Saharan Africa. Vaccine. 2013;31(Suppl 5):F73-4.
45. Huchko MJ, Bukusi EA, Cohen CR. Building capacity for cervical cancer screening in outpatient HIV clinics in the Nyanza province of western Kenya. Int J Gynaecol Obstet. 2011;114:106-10.
46. Rosser JI, Zakaras JM, Hamisi S, Huchko MJ. Men's knowledge and attitudes about cervical cancer screening in Kenya. BMC Womens Health. 2014;14:138.
47. Mutyaba T, Mirembe F, Sandin S, Weiderpass E. Male partner involvement in reducing loss to follow-up after cervical cancer screening in Uganda. Int J Gynaecol Obstet. 2009;107:103-6.
48. Cooper D, Mantell JE, Moodley J, Mall S. The HIV epidemic and sexual and reproductive health policy integration: views of South African policymakers. BMC Public Health. 2015;15:217.
49. Washington S, Owuor K, Turan JM, Steinfeld RL, Onono M, Shade SB, et al. The effect of integration of HIV care and treatment into antenatal care clinics on mother-to-child HIV transmission and maternal outcomes in Nyanza, Kenya: results from the SHAIP cluster randomized controlled trial. J Acquir Immune Defic Syndr. 2015;69(5):e164-71.